Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 121(12): 4700-11, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22105174

RESUMEN

Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary thyroid carcinomas (BRAF(V600E)) in thyroid follicular cells in a doxycycline-inducible (dox-inducible) manner. Upon dox induction of BRAF(V600E), the mice developed highly penetrant and poorly differentiated thyroid tumors. Discontinuation of dox extinguished BRAF(V600E) expression and reestablished thyroid follicular architecture and normal thyroid histology. Switching on BRAF(V600E) rapidly induced hypothyroidism and virtually abolished thyroid-specific gene expression and RAI incorporation, all of which were restored to near basal levels upon discontinuation of dox. Treatment of mice with these cancers with small molecule inhibitors of either MEK or mutant BRAF reduced their proliferative index and partially restored thyroid-specific gene expression. Strikingly, treatment with the MAPK pathway inhibitors rendered the tumor cells susceptible to a therapeutic dose of RAI. Our data show that thyroid tumors carrying BRAF(V600E) mutations are exquisitely dependent on the oncoprotein for viability and that genetic or pharmacological inhibition of its expression or activity is associated with tumor regression and restoration of RAI uptake in vivo in mice. These findings have potentially significant clinical ramifications.


Asunto(s)
Antineoplásicos/uso terapéutico , Carcinoma Papilar/tratamiento farmacológico , Indoles/uso terapéutico , Radioisótopos de Yodo/farmacocinética , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteínas de Neoplasias/fisiología , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas B-raf/fisiología , Sulfonamidas/uso terapéutico , Neoplasias de la Tiroides/tratamiento farmacológico , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Apoptosis/efectos de los fármacos , Benzamidas/administración & dosificación , Benzamidas/farmacología , Benzamidas/uso terapéutico , Benzamidas/toxicidad , Carcinoma Papilar/genética , Carcinoma Papilar/metabolismo , Carcinoma Papilar/patología , Daño del ADN , Difenilamina/administración & dosificación , Difenilamina/análogos & derivados , Difenilamina/farmacología , Difenilamina/uso terapéutico , Difenilamina/toxicidad , Doxorrubicina/farmacología , Ensayos de Selección de Medicamentos Antitumorales , Activación Enzimática/efectos de los fármacos , Genes Sintéticos/efectos de los fármacos , Humanos , Indoles/administración & dosificación , Indoles/farmacología , Indoles/toxicidad , MAP Quinasa Quinasa 1/antagonistas & inhibidores , Sistema de Señalización de MAP Quinasas/fisiología , Ratones , Ratones Transgénicos , Mutación Missense , Proteínas de Neoplasias/genética , Mutación Puntual , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/toxicidad , Proteínas Proto-Oncogénicas B-raf/genética , Sulfonamidas/administración & dosificación , Sulfonamidas/farmacología , Sulfonamidas/toxicidad , Glándula Tiroides/metabolismo , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/metabolismo , Neoplasias de la Tiroides/patología , Vemurafenib
2.
Biochem J ; 379(Pt 1): 71-8, 2004 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-14728600

RESUMEN

Many commonly used drugs, such as psoralen and cisplatin, can generate a very unique type of DNA damage, namely ICL (interstrand cross-link). An ICL can severely block DNA replication and transcription and cause programmed cell death. The molecular mechanism of repairing the ICL damage has not been well established. We have studied the role of XPF (xeroderma pigmentosum group F) protein in psoralen-induced ICL-mediated DNA repair and mutagenesis. The results obtained from our mutagenesis studies revealed a very similar mutation frequency in both human normal fibroblast cells and XPF cells. The mutation spectra generated in both cells, however, were very different: most of the mutations generated in the normal fibroblast cells were T167-->A transversions, whereas most of the mutations generated in the XPF cells were T167-->G transversions. When a wild-type XPF gene cDNA was stably transfected into the XPF cells, the T167-->A mutations were increased and the T167-->G mutations were decreased. We also determined the DNA repair capability of the XPF cells using both the host-cell reactivation and the in vitro DNA repair assays. The results obtained from the host-cell reactivation experiments revealed an effective reactivation of a luciferase reporter gene from the psoralen-damaged plasmid in the XPF cells. The results obtained from the in vitro DNA repair experiments demonstrated that the XPF nuclear extract is normal in introducing dual incisions during the nucleotide excision repair process. These results suggest that the XPF protein has important roles in the psoralen ICL-mediated DNA repair and mutagenesis.


Asunto(s)
Reactivos de Enlaces Cruzados/farmacología , Daño del ADN , Reparación del ADN/fisiología , ADN Recombinante/efectos de los fármacos , Proteínas de Unión al ADN/fisiología , Mutagénesis , Oligonucleótidos/farmacología , Trioxsaleno/farmacología , Xerodermia Pigmentosa/genética , Secuencia de Bases , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Células Cultivadas/efectos de la radiación , Aductos de ADN/metabolismo , Reparación del ADN/genética , ADN Complementario/genética , ADN Recombinante/genética , ADN Recombinante/efectos de la radiación , Proteínas de Unión al ADN/deficiencia , Proteínas de Unión al ADN/genética , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Fibroblastos/efectos de la radiación , Genes Reporteros , Genes Supresores , Genes Sintéticos/efectos de los fármacos , Genes Sintéticos/efectos de la radiación , Humanos , Luciferasas/biosíntesis , Luciferasas/genética , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Fotoquímica , Plásmidos/efectos de los fármacos , Plásmidos/efectos de la radiación , ARN de Transferencia/genética , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , Transfección , Trioxsaleno/análogos & derivados , Rayos Ultravioleta , Xerodermia Pigmentosa/metabolismo , Xerodermia Pigmentosa/patología
3.
Mutat Res ; 327(1-2): 121-9, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7870081

RESUMEN

The goal of this study was to determine if inhalation of benzene leads to an increase in the mutant frequencies in the tissues of male C57BL/6 mice. Mutant frequencies were measured using a previously described assay in which bacteriophage lambda lacI transgenes are rescued from mouse genomic DNA as infectious phage and scored for their LacI phenotype. Eight experimental mice were exposed to a target concentration of 300 ppm of benzene for 6 h/day x 5 days/week x 12 weeks, and eight control mice were treated similarly except that they were not exposed to benzene. Mutant frequencies were calculated as the ratio of LacI-/total phage recovered from organs of interest. The mean mutant frequency measured in lung tissues of mice exposed to benzene was (10.6 +/- 1.4) x 10(-5), which is about 1.7-fold higher than that of the unexposed controls. In spleen tissues from benzene-exposed mice the mean mutation frequency was (12.6 +/- 4.1) x 10(-5), which is about 1.5-fold higher than that of spleen tissues from unexposed controls. The differences in mean mutant frequencies between benzene-exposed and unexposed lung and spleen tissues are statistically significant. In liver tissues, however, the mean mutant frequencies of benzene-exposed mice and unexposed mice are not significantly different. These results demonstrate that inhaled benzene results in a statistically significant increase in the mutant frequencies in lung and spleen, but not in liver tissues of mice.


Asunto(s)
Proteínas Bacterianas/genética , Benceno/toxicidad , Proteínas de Escherichia coli , Genes Reporteros/efectos de los fármacos , Genes Sintéticos/efectos de los fármacos , Pulmón/efectos de los fármacos , Pruebas de Mutagenicidad , Proteínas Represoras/genética , Bazo/efectos de los fármacos , Administración por Inhalación , Animales , Proteínas Bacterianas/biosíntesis , Bacteriófago lambda/efectos de los fármacos , Bacteriófago lambda/genética , Benceno/administración & dosificación , ADN Recombinante/genética , ADN Recombinante/aislamiento & purificación , Inducción Enzimática , Escherichia coli/genética , Regulación Bacteriana de la Expresión Génica , Vectores Genéticos/efectos de los fármacos , Vectores Genéticos/genética , Represoras Lac , Hígado/efectos de los fármacos , Hígado/metabolismo , Pulmón/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Especificidad de Órganos , Proteínas Recombinantes de Fusión/genética , Bazo/metabolismo , beta-Galactosidasa/biosíntesis
5.
Mutagenesis ; 8(1): 7-10, 1993 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8450770

RESUMEN

A transgenic mouse strain with a high copy number of rescuable lacZ sequences was evaluated for its effectiveness in detecting lacZ- mutations in selected tissues. Procarbazine, cyclophosphamide, ethylnitrosourea, 7,12-dimethylbenz[a]anthracene (DMBA), acrylamide and chlorambucil were tested following either single or repeated dosing regimens. Bone marrow, liver, skin and testis tissues were selected to assess as target sites for mutation. Bone marrow, liver and testis tissues were examined for mutation following exposures to ethylnitrosourea and chlorambucil. Increased mutant frequencies were found for both chemicals in all three tissues. Bone marrow tissue was examined for mutation following procarbazine, cyclophosphamide and acrylamide exposures, and skin was examined for mutation following dermal application of DMBA. Mutation induction was observed in all cases. The results obtained from this investigation demonstrate the applicability of this transgenic mouse as an effective model to detect and analyze gene mutation in selected organs including germinal tissues. Studies of organotrophic chemical mutagens and carcinogens are possible with this model as are studies of the susceptibility of germinal tissues to mutagen exposures.


Asunto(s)
Bioensayo , Ratones Transgénicos/genética , Mutágenos/análisis , Animales , Daño del ADN , Relación Dosis-Respuesta a Droga , Genes Sintéticos/efectos de los fármacos , Masculino , Ratones , Pruebas de Mutagenicidad/métodos , Especificidad de Órganos , beta-Galactosidasa/genética
6.
Cell Mol Neurobiol ; 10(4): 485-95, 1990 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2091832

RESUMEN

1. Amyloid plaques found in the brains of Alzheimer's diseased patients are composed of the 42 amino acid beta-amyloid peptide (BAP) which is processed out of the larger amyloid precursor protein (APP). 2. To study the regulation of the APP gene expression, we have isolated the promoter region of this angle of this single-copy gene and produced a reporter gene system to determine if the promoter is responsive to agents that may cause the overproduction of APP leading to the abnormal accumulation of plaques in AD. 3. The promoter contains sequences homologous to heat shock elements, AP-1 binding sites, and phorbol ester-inducible sequences as well as GG-rich regions found in other constitutively expressed genes. 4. We show here that this promoter is inducible in cultured cells by interleukin-1 (IL-1) in a transient assay system and that the HSE and AP-1 binding site are required for this inducibility. 5. This induction of transcription from the APP promoter implies that this gene is responsive to tropic and/or trophic agents which may be present in the diseased brain.


Asunto(s)
Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/efectos de los fármacos , Genes Sintéticos/efectos de los fármacos , Interleucina-1/farmacología , Regiones Promotoras Genéticas/efectos de los fármacos , Precursores de Proteínas/efectos de los fármacos , Péptidos beta-Amiloides/genética , Animales , Secuencia de Bases , Cromosomas Humanos Par 21 , Humanos , Ratones , Datos de Secuencia Molecular , Precursores de Proteínas/genética , Proteínas Recombinantes/farmacología , Regulación hacia Arriba
7.
Mutat Res ; 146(2): 149-54, 1985 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2993877

RESUMEN

We used alkA'-lacZ' and umuC'-lacZ' fused genes and determined the ability of various alkylating agents to induce adaptive and SOS responses. The degree of induction of expression of these genes was quantitatively measured by a simple colorimetric assay of beta-galactosidase activity. SN1 type methylating agents, such as N-methyl-N'-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea, were more effective inducers for the alkA than for the umuC system, while SN1 type ethylating agents, such as N-ethyl-N'-nitro-N-nitrosoguanidine and N-ethyl-N-nitrosourea, were more potent inducers for the umuC than for the alkA system. Similar but less striking effects on the two systems were obtained with SN2 type alkylating agents.


Asunto(s)
Alquilantes/farmacología , ADN Glicosilasas , ADN Ligasas/biosíntesis , Reparación del ADN , Operón Lac , Polinucleótido Ligasas/biosíntesis , Proteínas Bacterianas/genética , ADN Ligasas/genética , Relación Dosis-Respuesta a Droga , Inducción Enzimática/efectos de los fármacos , Escherichia coli/genética , Escherichia coli/metabolismo , Etilnitrosourea/farmacología , Genes Bacterianos , Genes Sintéticos/efectos de los fármacos , Guanina/metabolismo , Metilación , Metilnitronitrosoguanidina/farmacología , Metilnitrosourea/farmacología , N-Glicosil Hidrolasas/genética , beta-Galactosidasa/biosíntesis , beta-Galactosidasa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA